Comparative Pharmacology
Head-to-head clinical analysis: ESTRADIOL AND NORETHINDRONE ACETATE versus MEGACE ES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRADIOL AND NORETHINDRONE ACETATE versus MEGACE ES.
ESTRADIOL AND NORETHINDRONE ACETATE vs MEGACE ES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol is an estrogen that binds to estrogen receptors (ERα/ERβ) to regulate gene transcription involved in reproductive and non-reproductive tissues. Norethindrone acetate is a progestin that binds to progesterone receptors, inducing secretory endometrium and inhibiting gonadotropin secretion.
Megestrol acetate is a synthetic progestin that inhibits pituitary gonadotropin secretion, leading to suppression of ovarian and testicular hormone production. It also has antineoplastic effects possibly through local action on hormone-sensitive tissues and stimulates appetite via modulation of neuropeptide Y and other appetite-regulating factors.
1 tablet (estradiol 1 mg / norethindrone acetate 0.5 mg) orally once daily; adjust dose based on response and tolerability.
625 mg orally once daily (MEGACE ES suspension contains 625 mg/5 mL; shake well before use). For appetite stimulation in cachexia.
None Documented
None Documented
Estradiol: terminal ~12-14 hours; norethindrone acetate: terminal ~8-11 hours. Steady-state reached within 5-7 days.
Approximately 34 hours in plasma; steady-state achieved after 2-3 weeks of daily dosing.
Estradiol: primarily renal as metabolites (glucuronide and sulfate conjugates), ~90% in urine, ~10% in feces as bile. Norethindrone: urinary (50-70% as metabolites) and fecal (20-30%).
Primarily renal (≤1% unchanged) and biliary; extensive metabolism to inactive glucuronide conjugates excreted in feces.
Category D/X
Category C
Progestin
Progestin